Co-Diagnostics, Inc.·4

May 27, 4:03 PM ET

Murphy Edward L. 4

Research Summary

AI-generated summary

Updated

Co-Diagnostics (CODX) Director Edward L. Murphy Receives Award

What Happened
Edward L. Murphy, a director of Co-Diagnostics, Inc. (CODX), received 1,695 shares on May 23, 2026 as an award/vesting event (transaction code A) and a matching conversion/exercise of a derivative (transaction code M) for 1,695 shares. Both transactions show $0.00 per share, so no cash was paid or received; the recorded economic value of the transfer in the Form 4 is $0.

Key Details

  • Transaction date: May 23, 2026 (reported on Form 4 filed May 27, 2026).
  • Transactions: Award/acquisition (A) of 1,695 shares at $0.00; exercise/conversion of derivative (M) disposing of 1,695 derivative units at $0.00.
  • Reported dollar value: $0 (no cash exchanged in these records).
  • Shares owned after transaction: Not specified in the filing.
  • Footnote: Filing states these shares are part of previously granted restricted stock units (RSUs) awarded June 12, 2023; April 26, 2024; and August 13, 2025, which vest in scheduled installments (see F1).
  • Timeliness: Filing was made 4 days after the transaction date (filed May 27 for a May 23 event), consistent with normal Form 4 timing.

Context
This appears to be a routine vesting/conversion of RSUs into common shares (award plus conversion of a derivative); there was no open-market purchase or sale and no cash payment shown. For retail investors, such awards reflect compensation/vesting events rather than an independent bullish or bearish trade by the insider. The footnote indicates these shares come from multi-year RSU grants with scheduled vesting.